Remicade (infliximab) generated sales of US$7.9 billion in 2010 and is indicated for 7 conditions –what are they?
Which companies are known to be developing biosimilar versions of Pfizer/Takeda's Enbrel (etanercept)?
How might new branded development in the multi-kinase sector affect the biosimilar development of Bayer's Nexavar (sorafenib)?
What revenue generating lifecycle developments will offset the challenge of generic competition for Roche's Xeloda (capecitabine)?
Assessing additional sales potential from a valuable product fit
The multi-therapy drugs included in this report realised total sales in excess of US$70 billion in 2010. It is, therefore, hardly surprising that many are being targeted by generic companies for the development of either traditional bioequivalent generics, or as targets for the next wave of biosimilars.
The top selling multi-therapy drug in 2010 was Enbrel (etanercept), with sales reported separately by Amgen, Pfizer and Takeda amounting to a total of US$7,850 million. Remicade (infliximab) was a close second, with sales reported by Johnson & Johnson and Merck & Co totalling US$7,581 million in 2010. In third place was Abbott's Humira (adalimumab), with sales of US$6,738 million; while Roche reported global sales of Rituxan/MabThera (rituximab) worth US$6,094 million in 2010.
While the top five in terms of sales in 2010 were biologicals, a number of small molecule multi-therapy drugs have established a place among the market leaders and are worthy of attention as they will not face the same regulatory obstacles of biosimilars. These include AstraZeneca's Seroquel franchise, with revenue of US$5,302 million; Otsuka/Bristol-Myers Squibb's Abilify (aripiprazole) with sales reported by Otsuka amounting to US$4,266 million; and Novartis' Glivec/Gleevec (imatinib) with sales of US$4,265 million.
Generic and biosimilar opportunities: high risk, high reward?
|SOURCE S .... 104|
Copyright©2010 PR Newswire.
All rights reserved